Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека

The aim of the investigation was to obtain the transgenic mammalian cell line CHO-K1 that expresses recombinant human FGF2 and secretes it into cultural medium and to compare the abilities of a monolyer cell culture and the cells encapsulated in alginate microcapsules to produce and to secrete this...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Фактори експериментальної еволюції організмів
Datum:2013
Hauptverfasser: Рымарь, С.Е., Рачкевич, Н.О., Кулачко, А.В., Рубан, Т.А., Кордюм, В.А.
Format: Artikel
Sprache:Russian
Veröffentlicht: Інститут молекулярної біології і генетики НАН України 2013
Schlagworte:
Online Zugang:https://nasplib.isofts.kiev.ua/handle/123456789/177999
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Zitieren:Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека / С.Е. Рымарь, Н.О. Рачкевич, А.В. Кулачко, Т.А. Рубан, В.А. Кордюм // Фактори експериментальної еволюції організмів: Зб. наук. пр. — 2013. — Т. 13. — С. 326-330. — Бібліогр.: 12 назв. — рос.

Institution

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id nasplib_isofts_kiev_ua-123456789-177999
record_format dspace
spelling Рымарь, С.Е.
Рачкевич, Н.О.
Кулачко, А.В.
Рубан, Т.А.
Кордюм, В.А.
2021-02-17T15:44:04Z
2021-02-17T15:44:04Z
2013
Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека / С.Е. Рымарь, Н.О. Рачкевич, А.В. Кулачко, Т.А. Рубан, В.А. Кордюм // Фактори експериментальної еволюції організмів: Зб. наук. пр. — 2013. — Т. 13. — С. 326-330. — Бібліогр.: 12 назв. — рос.
2219-3782
https://nasplib.isofts.kiev.ua/handle/123456789/177999
The aim of the investigation was to obtain the transgenic mammalian cell line CHO-K1 that expresses recombinant human FGF2 and secretes it into cultural medium and to compare the abilities of a monolyer cell culture and the cells encapsulated in alginate microcapsules to produce and to secrete this protein. Methods. The non-viral gene transfer method, RT-PCR, Western blot analysis were used for the investigation. Results. The expression vector pC1-F contained the recombinant human FGF2 had been constructed. This vector was used for the CHO-K1 cells transfection. As a result, a stable transgenic cell line expressing FGF2 was obtained. A few positive signals were detected via Western blot analysis of the conditioned cultural media. The same protein products were revealed in a case of the conditioned cultural media where alginate microcapsules with the transgenic cells had been cultivated. Conclusion. Thus the obtained genetically modified CHO-K1 cells remain a sourсe of the recombinant human FGF2 after their encapsulation in alginate microcapsules. Key words: recombinant human FGF2, transfection, encapsulation, alginate microcapsule.
ru
Інститут молекулярної біології і генетики НАН України
Фактори експериментальної еволюції організмів
Генетика людини та медична генетика
Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека
Encapsulated genetically modified cells of CHO-K1 as source of human recombinant FGF2
Article
published earlier
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
title Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека
spellingShingle Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека
Рымарь, С.Е.
Рачкевич, Н.О.
Кулачко, А.В.
Рубан, Т.А.
Кордюм, В.А.
Генетика людини та медична генетика
title_short Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека
title_full Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека
title_fullStr Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека
title_full_unstemmed Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека
title_sort инкапсулированные генетически модифицированные клетки сно-к1 как источник рекомбинантного fgf2 человека
author Рымарь, С.Е.
Рачкевич, Н.О.
Кулачко, А.В.
Рубан, Т.А.
Кордюм, В.А.
author_facet Рымарь, С.Е.
Рачкевич, Н.О.
Кулачко, А.В.
Рубан, Т.А.
Кордюм, В.А.
topic Генетика людини та медична генетика
topic_facet Генетика людини та медична генетика
publishDate 2013
language Russian
container_title Фактори експериментальної еволюції організмів
publisher Інститут молекулярної біології і генетики НАН України
format Article
title_alt Encapsulated genetically modified cells of CHO-K1 as source of human recombinant FGF2
description The aim of the investigation was to obtain the transgenic mammalian cell line CHO-K1 that expresses recombinant human FGF2 and secretes it into cultural medium and to compare the abilities of a monolyer cell culture and the cells encapsulated in alginate microcapsules to produce and to secrete this protein. Methods. The non-viral gene transfer method, RT-PCR, Western blot analysis were used for the investigation. Results. The expression vector pC1-F contained the recombinant human FGF2 had been constructed. This vector was used for the CHO-K1 cells transfection. As a result, a stable transgenic cell line expressing FGF2 was obtained. A few positive signals were detected via Western blot analysis of the conditioned cultural media. The same protein products were revealed in a case of the conditioned cultural media where alginate microcapsules with the transgenic cells had been cultivated. Conclusion. Thus the obtained genetically modified CHO-K1 cells remain a sourсe of the recombinant human FGF2 after their encapsulation in alginate microcapsules. Key words: recombinant human FGF2, transfection, encapsulation, alginate microcapsule.
issn 2219-3782
url https://nasplib.isofts.kiev.ua/handle/123456789/177999
citation_txt Инкапсулированные генетически модифицированные клетки СНО-К1 как источник рекомбинантного FGF2 человека / С.Е. Рымарь, Н.О. Рачкевич, А.В. Кулачко, Т.А. Рубан, В.А. Кордюм // Фактори експериментальної еволюції організмів: Зб. наук. пр. — 2013. — Т. 13. — С. 326-330. — Бібліогр.: 12 назв. — рос.
work_keys_str_mv AT rymarʹse inkapsulirovannyegenetičeskimodificirovannyekletkisnok1kakistočnikrekombinantnogofgf2čeloveka
AT račkevično inkapsulirovannyegenetičeskimodificirovannyekletkisnok1kakistočnikrekombinantnogofgf2čeloveka
AT kulačkoav inkapsulirovannyegenetičeskimodificirovannyekletkisnok1kakistočnikrekombinantnogofgf2čeloveka
AT rubanta inkapsulirovannyegenetičeskimodificirovannyekletkisnok1kakistočnikrekombinantnogofgf2čeloveka
AT kordûmva inkapsulirovannyegenetičeskimodificirovannyekletkisnok1kakistočnikrekombinantnogofgf2čeloveka
AT rymarʹse encapsulatedgeneticallymodifiedcellsofchok1assourceofhumanrecombinantfgf2
AT račkevično encapsulatedgeneticallymodifiedcellsofchok1assourceofhumanrecombinantfgf2
AT kulačkoav encapsulatedgeneticallymodifiedcellsofchok1assourceofhumanrecombinantfgf2
AT rubanta encapsulatedgeneticallymodifiedcellsofchok1assourceofhumanrecombinantfgf2
AT kordûmva encapsulatedgeneticallymodifiedcellsofchok1assourceofhumanrecombinantfgf2
first_indexed 2025-11-25T22:45:17Z
last_indexed 2025-11-25T22:45:17Z
_version_ 1850570988637388800
fulltext 326 NEUMERZITSKAYA L.V., KLIMENKO S.W., KOVAL G.M., WERBILENKO R.M., V.N. SHKARUPA Si «National S ientific Center for Radiation Medicine NAM S of Ukraine» Ukraine, 04050, Kiev, Melnikov str., 53, e-mail: lneum@bigmir.net STUDY OF CHROMOSOMAL ABNORMALITIES IN THE SOMATIC CELLS OF PATIENTS WITH THYROID CANCER WHO SUFFERED FROM THE CHERNOBYL ACCIDENT Aims. Research level and spectrum of chromosomal aberrations in peripheral blood lymphocytes of patients with thyroid cancer, which were last ionizing radiation due to the Chernobyl accident. Methods. ytogenetic analysis of human lymphocytes. Results. Cytogenetic studies of peripheral blood lymphocytes of patients with thyroid cancer. This group of patients previously exposed to radiation. The frequency of chromosomal aberrations in peripheral blood lymphocytes of patients with higher levels of spontaneous and significantly higher than the control group. Key words: thyroid cancer, chromosome aberrations, radiation. . ., . ., . ., . ., . . , 03680, . , . . , 150, e-mail: s.y.rymar@imbg.org.ua « » , 04114, . , . , 67 - 1 FGF2 - ( , , .) - - ( I , , , - , ). - . - - - , . - , , , , - . , - , - , , . , - - , - [1, 2]. - [3]. . , - 1, FGF2 , FGF2 . FGF2 , - , - , , , - , , - , , - [3]. , - , . - FGF2 - . 327 pUC 28, pJET2.1-blunt, pEGFP-C1 (Clontech), Escherichia col : DH10 , HB 101,XL 1, CHO-K1 ( - ). , , , E.coli, , [4]. - - ( ). - . CHO-K1, pC1-F ( . 1), G418 (200 / ). - 1 - NucleoSpin RNA II (Macherey-Nagel Inc.). FGF2 - 1 - - , - (Thermo scientific). FGF2 , - - . F 10, - 10 % (Sigma), F10 - , . 1,5–2 - , 10 % 0,015 % . - 10 % - [5] - - online Millipore (millipore.com/immunodetection/ id3/westernblotting), - FGF2 IgG , , (Sigma, ). - [6]: ( 7,4) - 1 ( 107) 1,5 % - , (0,9 % NaCl). 29 g, 102 m l2. 30 l2 , , F10. FGF2 - F10 - . - , - CHO-K1, - FGF2 . - - FGF2 - , - 4433 bp Kan (R) / Neo (R) CDS(FGF2) Enhancer (72 tandem repeats) enhancer region P CMV IE SV40 ori ColE1 ori F1 ori P TATA box Nh e Sa .1 pC1-F pC1-F 328 , pEGFP-C1 (Clontech). - - 1 - (pC1-F) - (25 Da) - G418. FGF2 - - - . , - - , - - 1 , - - - FGF2 - - 1 ( . 2, ). - . , FGF2 , - , - – [7], , . - - , , , - 55 35 . FGF2, , 18 , E. coli, , FGF2 . - , FGF2 - [8–10] . , - , , . - FGF2 [11]. - 1 - , 1EGFP, - - ( . 3, ). - , , , GFP. , - , - , -L- [12]. 2. FGF2 - 1: – - ( FGF2): 1 – - 1, 2 – - 1, « » pC1EGFP, 3 – , pC1-F, 4 – 1kb DNA ladder(Fermentas), 5 – ( pC1-F); – - 1, 1FGF2, , :1 – FGF2 (20 ), 2 – , - - 1, 1-F, 3 – - 1, 1-F, 4 – , - 1, 1 GFP, 6, 7 – , , - 1-F. 329 . 3. - 1, pC1EGFP, - ( – , – ) - , - 1, - , , FGF2, - , - - ( . 2, , . 2). , - - 1 - FGF2 - , - - . - - , in vivo. 1. Krishnamurthy N.V., Gimi B. Encapsulated cell grafts to treat cellular deficiencies and dysfunction // Crit Rev. Biomed. Eng. – 2011. – Vol. 39, 6. – P. 473–491. 2. Hernández R.M., Orive G., Murua A., Pedraz J.L. Microcapsules and microcarriers for in situ cell delivery // Advanced Drug Delivery Reviews. – 2010. – Vol. 62. – P. 711–730. 3. Yun Y.R., Won J.E., Jeon E., Lee S., Kang W., Jo H., Jang J.H., Shin U.S., Kim H.W. Fibroblast growth factors: biology, function, and application for tissue regeneration // J. Tissue Eng. – 2010. – P. 1–18. 4. Sambrook J., Fritsch E.F., Maniatis T. Molecular cloning // Cold Spring Harbor Lab. Press. – 1989. – Vol. 1. – P. 568. 5. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 // Nature. – 1970. – Vol. 227, 5229. – P. 680–685. 6. Cohen J., Zaleski K.L., Nourissat G., Yaremchuk M.J. Survival of porcine mesenchymal stem cells over the alginate recovered method // J. Biomed. Mater. Res. Part A. – 2010. – 96 A. – P. 93–99. 7. Zehe C, Engling A, Wegehingel S, Schäfer T, Nickel W. Cell-surface heparan sulfate proteoglycans are essential components of the unconventional export machinery of FGF-2 // Proc. Natl. Acad. Sci. USA. – 2006. – Vol. 103. – P. 15479–15484. 8. Soulet F., Bailly K., Roga S., Bouche G. Exogenously added FGF2 to NIH3T3 cells interacts with nuclear ribosomal S6 kinase in cell cycle-dependent manner // JBC. – 2005. – Vol. 280. – P. 25604–25610. 9. Bonnet H., Filhol O., Truchet I., Bouche G. FGF2 binds to the regulatory subunit of CK2 and directly stimulates CK2 activity toward nucleolin // JBC. – 1996. – Vol. 271. – P. 24781–24787. 10. Van den Berghe L., Laurell H., Bugler B. FIF, a nuclear putatively antiapoptotic factor, interacts specifically with FGF2 // Mol. Endocrinol. – 2000. – Vol. 14. – P. 1709–1724. 11. Herr B., Ornitz D.M., Sasisekharan R., Venkataraman G., Waksman G. Heparin-induced Self-association of Fibroblast Growth Factor-2 // JBC. – 1997. – Vol. 272. – P. 16382–16389. 12. Darrabie M.D., Kendall W.F.Jr., Opara E.C. Characteristics of Poly-L-Ornithine-coated alginate microcapsules // Biomaterials. – 2005. – Vol. 26, 34. – P. 6846–6852. 100 m 50 m 330 RYMAR S.E., RACHKEVICH N.O., KULACHKO A.V., RUBAN T.A., KORDIUM V.A. Institute of Molecular Biology and Genetics of NASU Ukraine, 03680, Kyiv, Acad. Zabolotny str., 150, e-mail: s.y.rymar@imbg.org.ua SI «Institute of Genetic and Regenarative Medicine» NASMU Ukraine, 04114, Kyiv, Vyshgorodska str., 67 ENCAPSULATED GENETICALLY MODIFIED CELLS OF CHO-K1 AS SOUR E OF HUMAN RECOMBINANT FGF2 The aim of the investigation was to obtain the transgenic mammalian cell line CHO-K1 that expresses recombinant human FGF2 and secretes it into cultural medium and to compare the abilities of a monolyer cell culture and the cells encapsulated in alginate microcapsules to produce and to secrete this protein. Methods. The non-viral gene transfer method, RT-PCR, Western blot analysis were used for the investigation. Results. The expression vector pC1-F contained the recombinant human FGF2 had been constructed. This vector was used for the CHO-K1 cells transfection. As a result, a stable transgenic cell line expressing FGF2 was obtained. A few positive signals were detected via Western blot analysis of the conditioned cultural media. The same protein products were revealed in a case of the conditioned cultural media where alginate microcapsules with the transgenic cells had been cultivated. Conclusion. Thus the obtained genetically modified CHO-K1 cells remain a sour e of the recombinant human FGF2 after their encapsulation in alginate microcapsules. Key words: recombinant human FGF2, transfection, encapsulation, alginate microcapsule. . . « » , 79000, . , . 31- , e-mail:katja.sosnina@gmail.com / 14 . . HLA-G ’ , , ’ , [15]. , - , , , . - HLA- , b HLA-G, HLA- , HLA-F [4, 10, 15]. , HLA I- II- HLA- [8, 9, 17, 11]. , – , HLA- , - . HLA- : HLA-G HLA-E HLA-F - [3, 5, 15]. HLA- G. , - HLA-G - ILT2 ILT4 KIR2DL4. HLA-G - , . HLA-G, ILT-2 / - , . , HLA-G - ’ - , [1,11]. HLA-G